Merck Sharp & Dohme Research GmbH
CIK 1665244 · last filed 2016-02-10
Merck Sharp & Dohme Research GmbH is a corporate insider who has filed 1 SEC Form 4 insider transactions across 1 company since 2016. The most recent filing, for BGNE, was dated Feb 10, 2016. The firm reports its address in Lucerne 6, V8. 2 SEC filings were submitted jointly with BeiGene, Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
1
$0
Filer Profile
LUCERNE 6, V8 CH-6000
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BeOne Medicines Ltd. (BGNE) Delisted | 10%+ Owner | 5,128,205 | $184.71 | $947.23M | $0 | 1 | 2016-02-10 |
Recent Filings
1 filing| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-02-10 | BeOne Medicines Ltd. (BGNE) Delisted | Mixed | +94,767,114 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.